Breaking News, Financial News

Financial Report: Abbott 2Q

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Abbott 2Q Revenues: $7.3 billion (+15%) 2Q Earnings: $1.3 billion (+34%) YTD Revenues: $14.1 billion (+14%) YTD Earnings: $2.3 billion (+34%) Comments: Worldwide pharmaceutical sales increased 17% percent in the quarter to $4.1 billion, driven by Humira, Niaspan and Kaletra. Humira sales were $1.1 billion in the quarter (+48%), Niaspan sales were $194 million  (+14%) and Kaletra sales were $355 million (+13%). R&D expenses grew 13% to $657 million in the quarter. Pharmaceutica...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters